Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.

Blood - 1 Oct 2005

Stam Ronald W, den Boer Monique L, Schneider Pauline, Nollau Peter, Horstmann Martin, Beverloo H Berna, van der Voort Ella, Valsecchi Maria G, de Lorenzo Paola, Sallan Stephen E, Armstrong Scott A, Pieters Rob

Abstract excerpt

Acute lymphoblastic leukemia (ALL) in infants is characterized by rearrangements of the mixed lineage leukemia (MLL) gene, drug resistance, and a poor treatment outcome. Therefore, novel therapeutic strategies are needed to improve prognosis. Recently, we showed that FLT3 is highly expressed in MLL rearranged ALL (MLL). Here we demonstrate FLT3 expression in infants with MLL (n = 41) to be significantly higher...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Inhibitors
Share to Gene Duplication

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Rearrangement

Share to Immunoprecipitation

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Staurosporine

Share to Tetrazolium Salts

Share to Thiazoles

Source

Identifiers

PMID: 15956279
DOI: 10.1182/blood-2004-09-3667

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.PMID 15956279Read ↗

Treatment of infant leukemias: challenge and promiseSemantic proximity Read ↗

FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer.Semantic proximity Read ↗

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.Semantic proximity Read ↗

Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

FLT3 as a therapeutic target in childhood acute leukemia.Semantic proximity Read ↗

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.Semantic proximity Read ↗

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.Semantic proximity Read ↗

FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.Semantic proximity Read ↗

FLT3 mutations in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

MLL fusion-driven activation of<i>CDK6</i>potentiates proliferation in<i>MLL-</i>rearranged infant ALLSemantic proximity Read ↗

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.Semantic proximity Read ↗

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.